Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse

NCT05559788 is registered in ClinicalTrials.gov with Fu chengcheng PhD as lead sponsor.

NCT NCT05559788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05559788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse
Lead sponsor
Fu chengcheng PhD
Phase
Observational
Overall status
Unknown status
Start date
September 20, 2022
Completion date
June 1, 2025
Enrollment
34 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma at first relapse